Answer
Repeated rifampicin dosing reduces exposure to ertugliflozin in Steglatro, decreasing AUC by 39% and maximum plasma concentration by 15%, but this is not considered clinically relevant and no dose adjustment is recommended.
Sources for this answer
- Steglatro 5 mg and 15 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 9Document updated
Sources checked